-
This latest expansion brings Lilly’s totaled pledge investment at the site to more than $13 billion and potentially 1,300 jobs.
-
Eli Lilly will more than double its investment at its manufacturing plant in Lebanon to make more of its popular weight loss drugs.
-
Novo Nordisk along with Sanofi and Indianapolis-based Eli Lilly control over 90 percent of the world insulin market.
-
Indiana manufacturers want to continue to use certain types of toxic PFAS. A state House bill, HB 1399, aims to change the definition of PFAS under Indiana law to exclude the specific chemicals they want to use.
-
Eli Lilly announced Thursday a new telehealth service for patients with diabetes, migraines and obesity.
-
Officials with Eli Lilly said the new facility will help them produce state-of-the-art drugs – including the company's new diabetes and obesity drug, Mounjaro.
-
The company’s Humalog and Humalin insulins will have a 70 percent price cut later this year. Its non-branded insulin will also receive a price cut.
-
A court temporarily halts Biden’s student loan forgiveness, protestors rally outside Eli Lilly demanding lower insulin costs and we sit down with two of the three candidates running for Indiana’s Secretary of State.
-
Advocates with T1International said what Eli Lilly has done so far to lower insulin prices is still not enough.
-
Much of the uncertainty surrounding the economic impact of the new abortion law is due to the fact that the constitutional right to abortion had been upheld for nearly a half century.